A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01435629

Enrollment

Registered

2011-09-16

Start date

2012-11-22

Completion date

2015-12-04

Last updated

2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achondroplasia, Genetic Disorder

Brief summary

This study is conducted in Japan. The aim of the study is to evaluate the efficacy of somatropin (Norditropin®) on adult height (cm) in patients with achondroplasia / hypochondroplasia enrolled in the GH-1941 study (NCT01516229).

Interventions

DRUGsomatropin

Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients who were enrolled in the GH-1941 study (1997 to 2006) and expected to theoretically reach the adult height within the study period

Design outcomes

Primary

Measure	Time frame
To collect change data of adult height (cm) of patients treated with Norditropin® and evaluate the long-term efficacy	At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age

Secondary

Measure	Time frame
To monitor the patients to see if they undergo lower limb lengthening	At year 1, 2, 3, 4, and 5 after the patient has reached adult height or is 18 of age

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026